Key result
Oral lenalidomide, dexamethasone, and melphalan shows initial feasibility in cardiac AL amyloidosis.
Key points are not available for this paper at this time.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Merlini et al. (2013) studied this question. An oral regimen of lenalidomide, dexamethasone, and low-dose melphalan was piloted in 25 patients with light chain amyloidosis, mostly with cardiac involvement.
Synapse has enriched 5 related papers. Consider them for comparative context: